Targeted Therapy & Precision Oncology
Part of Healthcare - Oncology
 LLY | Eli Lilly & Co. | $1.0t | $1281.80 | +0.2% | 1.3M |
 RVMD | Revolution Medicines, Inc. Common Stock | $44.3b | $186.27 | +1.5% | 949.4K |
 INCY | Incyte Genomics Inc | $23.4b | $116.59 | +2.5% | 1.5M |
 JAZZ | Jazz Pharmaceuticals, Inc. | $15.3b | $206.82 | +0.6% | 463.9K |
 EXEL | Exelixis Inc | $14.5b | $65.35 | +0.3% | 1.2M |
 CORT | Corcept Therapeutics Inc. | $12.6b | $87.59 | -0.0% | 763.1K |
 HALO | Halozyme Therapeutics, Inc. | $12.5b | $128.52 | +0.2% | 1.1M |
 NUVL | Nuvalent, Inc. Class A Common Stock | $9.8b | $123.96 | 0.0% | N/A |
 COGT | Cogent Biosciences, Inc. Common Stock | $5.4b | $32.02 | +3.8% | 1.4M |
 ERAS | Erasca, Inc. Common Stock | $5.2b | $15.22 | +1.2% | 4.1M |
 RLAY | Relay Therapeutics, Inc. Common Stock | $4.2b | $18.83 | +4.0% | 1.8M |
 TNGX | Tango Therapeutics, Inc. | $3.9b | $22.90 | +3.5% | 2.7M |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | $3.6b | $33.49 | +1.9% | 702.6K |
 CELC | Celcuity Inc. Common Stock | $3.5b | $68.11 | +3.8% | 681.4K |
 ELVN | Enliven Therapeutics, Inc. Common Stock | $3.4b | $43.69 | +5.5% | 1.3M |
 PBLS | Parabilis Medicines, Inc. Common Stock | $3.2b | $26.56 | +7.0% | 1.2M |
 NRIX | Nurix Therapeutics, Inc. Common stock | $2.4b | $26.75 | +4.2% | 2.0M |
 IMNM | Immunome, Inc. | $2.4b | $18.77 | +4.9% | 948.7K |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | $2.2b | $21.52 | -0.0% | 3.0M |
 URGN | UroGen Pharma Ltd. Ordinary Shares | $2.0b | $33.91 | -0.3% | 855.8K |
 BHVN | Biohaven Ltd. | $1.9b | $15.29 | +5.2% | 1.9M |
 VIR | Vir Biotechnology, Inc. Common Stock | $1.9b | $11.56 | +5.0% | 1.5M |
 NUVB | Nuvation Bio Inc. | $1.8b | $4.54 | -0.2% | 4.2M |
 ZYME | Zymeworks Inc. | $1.8b | $28.87 | +2.0% | 776.2K |
 NVCR | NovoCure Limited Ordinary Shares | $1.7b | $14.62 | +1.5% | 1.1M |
 TYRA | Tyra Biosciences, Inc. Common Stock | $1.4b | $21.56 | +4.8% | 415.3K |
 AVBP | ArriVent BioPharma, Inc. Common Stock | $1.4b | $15.40 | +0.1% | 1.4M |
 DMRA | Damora Therapeutics, Inc. Ordinary Shares | $1.3b | $21.96 | +3.4% | 206.3K |
 ORIC | Oric Pharmaceuticals, Inc. Common Stock | $1.3b | $9.00 | +1.3% | 4.7M |
 KURA | Kura Oncology, Inc. | $0.9b | $9.90 | +1.6% | 1.4M |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | $0.9b | $10.65 | +1.3% | 1.0M |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.9b | $50.55 | +0.8% | 90.8K |
 GERN | Geron Corp | $0.8b | $1.15 | -0.4% | 5.4M |
 OLMA | Olema Pharmaceuticals, Inc. Common Stock | $0.7b | $7.05 | +6.0% | 1.9M |
 NVCT | Nuvectis Pharma, Inc. Common Stock | $0.7b | $18.42 | -2.1% | 125.1K |
 VSTM | Verastem, Inc. | $0.7b | $10.10 | +1.3% | 4.3M |
 FTH | Faeth Therapeutics, Inc. Common Stock | $0.5b | $19.19 | +14.1% | 590.0K |
 DCTH | Delcath Systems Inc | $0.5b | $14.73 | +1.5% | 204.0K |
 MNPR | Monopar Therapeutics Inc. Common Stock | $0.5b | $71.77 | +2.1% | 121.8K |
 PBYI | PUMA BIOTECHNOLOGY INC | $490.9m | $10.93 | +0.3% | 183.3K |
 ARVN | Arvinas, Inc | $484.5m | $7.46 | +1.2% | 679.7K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $384.0m | $3.22 | -0.6% | 1.4M |
 CCCC | C4 Therapeutics, Inc. | $362.9m | $3.21 | +7.2% | 3.8M |
 BBOT | BridgeBio Oncology Therapeutics, Inc. Common Stock | $311.9m | $2.69 | -0.8% | 1.6M |
 PRLD | Prelude Therapeutics Incorporated | $292.9m | $3.88 | +4.9% | 222.0K |
 TLSI | TriSalus Life Sciences, Inc. Common Stock | $266.0m | $3.81 | +6.1% | 110.5K |
 IMRX | Immuneering Corporation Class A Common Stock | $263.3m | $3.84 | +2.7% | 554.9K |
 STRO | Sutro Biopharma, Inc. | $254.5m | $8.87 | -2.8% | 395.9K |
 ZNTL | Zentalis Pharmaceuticals, Inc. Common Stock | $238.6m | $1.98 | -3.6% | 1.3M |
 WHWK | Whitehawk Therapeutics, Inc. Common Stock | $210.9m | $3.32 | +5.7% | 242.5K |